A. Marin Muñiz*a (Mr), M. Díez Ferrera (Dr), P. Trias Sabriàa (Mr), L. Méndez Mangasa (Mrs), M. Plana Pesa (Mrs), F. Rivas Doyaguea (Mr), J. Tornero Saltoa (Mr), S. Santos Péreza (Prof), R. López Lisbonaa (Mrs)

a Hospital Universitari de Bellvitge, IDIBELL, L'Hospitalet De Llobregat, SPAIN

* amarinm@bellvitgehospital.cat


During the COVID-19 pandemic, the number of patients who required admission to the intensive care unit (ICU) and prolonged intubation (ETI) or a tracheotomy (TT) due to severe ARDS has increased.

Causes of persistent dyspnea after severe COVID-19 pneumonia include diffuse lung disease and

pulmonary embolism. However, other causes of persistent dyspnea need to be ruled out in COVID-19 ICUsurvivors, including iatrogenic tracheal stenosis (TS).

Iatrogenic TS account for 50% of the 15-20 patients evaluated every year in the laryngotracheal

multidisciplinary team (MDT) of our center. The management of these patients requires an individualized and multidisciplinary assessment, including Interventional Pulmonologists, Thoracic Surgeons and Otolaryngologists.

The objective of this study was to describe the cases of iatrogenic TS after severe pneumonia due to COVID-19.

Material and methods

A descriptive study of the cases of iatrogenic TS in COVID-19 ICU-survivors evaluated at our center’s MDT, from the end of the first wave to present.


A total of 10 patients were included, 70% were women, with a median age of 60 years [53.5-64.5]. The median ICU stay was 58.5 days [34-91]. All patients were intubated and 9 of them (90%) required TT, in 2 cases due to extubation failure. Symptoms at diagnosis included dyspnea in 3 (30%), stridor in 6 (60%) and 1 (10%) was asymptomatic. TS location was glottic in 2 (20%) and tracheal in 8 (80%). The main cause of TS was ring fracture secondary to TT (40%).


Iatrogenic TS is a rare cause of dyspnea in COVID-19 ICU-survivors, but it must be considered in these patients given the high number of patients who required prolonged ETI or TT during the COVID-19 pandemic.

Disclosure of funding source(s): none